The impact of CCL3L1 copy number in an HIV-1-infected white population

No abstract is available for this paper.

• Publication year

  2010

• Venue

  AIDS (London)

• Publication date

  2010-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/QAD.0b013e3283398294PMID 20549846
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human immunodeficiency virus serodiscordant couples on highly active antiretroviral therapies with undetectable viral load: conception by unprotected sexual intercourse or by assisted reproduction techniques?

  2010cited by this paper
• Mid‐dosing interval concentration of atazanavir and virological outcome in patients treated for HIV‐1 infection

  2010cited by this paper
• Determining Seminal Plasma Human Immunodeficiency Virus Type 1 Load in the Context of Efficient Highly Active Antiretroviral Therapy

  2009cited by this paper
• Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

  2009cited by this paper
• Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established?

  2009cited by this paper
• Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis

  2009cited by this paper
• The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells

  2009cited by this paper
• LTR real‐time PCR for HIV‐1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01)

  2009cited by this paper
• The immune response during acute HIV-1 infection: clues for vaccine development

  2009cited by this paper
• Early Virological and Immunological Response is Comparable between Nevirapine and RTV-boosted Atazanavir: An ARTEN Sub-analysis

  2009cited by this paper
• Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma

  2008cited by this paper
• Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis.

  2008cited by this paper
• LTR Real-Time PCR for HIV-1 DNA Quantitation in Blood Cells for Early Diagnosis in Infants Born to Seropositive Mothers Treated in HAART Area ( ANRS CO 01 )

  2008cited by this paper
• Is transmission of HIV-1 in non-viraemic serodiscordant couples possible?

  2008cited by this paper
• Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

  2008cited by this paper
• O223 Antiretroviral Pregnancy Registry (APR) at 10,000 prospective reports

  2008cited by this paper
• Durability of virologic response to etravirine is not affected by time to reach virologic response

  2008cited by this paper
• Host CCL3L1 Gene Copy Number in Relation to HIV-1-Specific CD4+ and CD8+ T-Cell Responses and Viral Load in South African Women

  2008cited by this paper
• Phase III TITAN week 96 final analysis: efficacy/safety of darunavir/r (DRV/r) vs. lopinavir/r (LPV/r) in LPV-naïve, treatment-experienced patients

  2008cited by this paper
• Viro-Immunologic Response to Ritonavir-Boosted or Unboosted Atazanavir in a Large Cohort of Multiply Treated Patients: The CARe Study

  2008cited by this paper
• Class-sparing regimens for initial treatment of HIV-1 infection.

  2008cited by this paper
• Resisting Immune Exhaustion in HIV-1 Infection

  2008cited by this paper
• HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors

  2008cited by this paper
• Treatment of acute HIV-1 infection: are we getting there?

  2008cited by this paper
• Acute HIV infection: the impact of anti‐retroviral treatment on cellular immune responses

  2007cited by this paper
• Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.

  2007cited by this paper
• HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype

  2007cited by this paper
• Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia

  2007cited by this paper
• Copy number variations of CCL3L1 and long-term prognosis of HIV-1 infection in asymptomatic HIV-infected Japanese with hemophilia

  2007cited by this paper
• CD4+ Count–Guided Interruption of Antiretroviral Treatment

  2007cited by this paper
• Postgenomic up-regulation of CCL3L1 expression in HTLV-2-infected persons curtails HIV-1 replication.

  2007cited by this paper
• 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures

  2006cited by this paper
• Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically

  2006cited by this paper
• Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts.

  2005cited by this paper
• HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication.

  2005cited by this paper
• The Influence of CCL3L1 Gene-Containing Segmental Duplications on HIV-1/AIDS Susceptibility

  2005cited by this paper
• Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression.

  2005cited by this paper
• Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

  2005cited by this paper
• Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

  2005cited by this paper
• Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions

  2004cited by this paper
• Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV

  2004influential reference
• Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes

  2004cited by this paper
• Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level

  2003cited by this paper
• Decrease in HIV-1 seminal shedding in men receiving highly active antiretroviral therapy: an 18 month longitudinal study (ANRS EP012).

  2002cited by this paper
• Assisted reproduction in HIV-1-serodifferent couples: the need for viral validation of processed semen

  2002cited by this paper
• Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV

  2000cited by this paper
• The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine.

  1999cited by this paper
• District of Columbia

  1896cited by this paper
• Journal of Medical Virology 78:877–882 (2006) Multicenter Quality Control of the Detection of HIV-1 Genome in Semen Before Medically Assisted Procreation

  year unknowncited by this paper

• New insights into transcription elongation control of HIV-1 latency and rebound.

  2023cites this paper
• HIV infection dynamics and viral rebound: Modeling results from humanized mice.

  2023cites this paper
• Towards a molecular profile of antiretroviral therapy-free HIV remission

  2022cites this paper
• Frailty and Aging in HIV— Status Post 13 Years of National Awareness

  2022cites this paper
• CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies

  2022cites this paper
• Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8+ T cells

  2022cites this paper
• Impact of Analytical Treatment Interruption on Burden and Diversification of HIV Peripheral Reservoir: A Pilot Study

  2021cites this paper
• Viral, inflammatory, and reservoir characteristics of posttreatment controllers

  2021cites this paper
• Transient viral replication during analytical treatment interruptions in SIV infected macaques can alter the rebound-competent viral reservoir

  2021cites this paper
• Antigen Presenting Cells Contribute to Persistent Immune Activation Despite Antiretroviral Therapy Initiation During Hyperacute HIV-1 Infection

  2021cites this paper
• Are Fc Gamma Receptor Polymorphisms Important in HIV-1 Infection Outcomes and Latent Reservoir Size?

  2021cites this paper
• Immunologic Control of HIV-1: What Have We Learned and Can We Induce It?

  2021cites this paper
• Predicting Post-treatment HIV Remission: Does Size of the Viral Reservoir Matter?

  2021cites this paper
• Cohort profile: the Netherlands Cohort Study on Acute HIV infection (NOVA), a prospective cohort study of people with acute or early HIV infection who immediately initiate HIV treatment

  2021cites this paper
• Atazanavir/ritonavir vs Efavirenz como primeira linha de tratamento em adultos vivendo com HIV

  2021cites this paper
• Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on‐going viral transcription

  2020cites this paper
• Virtual memory CD8+ T cells restrain the viral reservoir in HIV-1-infected patients with antiretroviral therapy through derepressing KIR-mediated inhibition

  2020cites this paper
• Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection.

  2020cites this paper
• Immunological approaches to HIV cure.

  2020cites this paper
• HIV RNA Rebound in Seminal Plasma after Antiretroviral Treatment Interruption

  2020cites this paper
• The importance of semen leukocytes in HIV-1 transmission and the development of prevention strategies

  2020cites this paper
• Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection

  2020cites this paper
• Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform.

  2019cites this paper
• Attenuation of macrophage IL-10 responses by HIV-1

  2019influential citation
• Memory CD4 + T-Cells Expressing HLA-DR Contribute to HIV Persistence During Prolonged Antiretroviral Therapy

  2019cites this paper
• Learning From the Exceptions: HIV Remission in Post-treatment Controllers

  2019cites this paper
• Effects of highly active antiretroviral therapy on semen parameters of a cohort of 770 HIV-1 infected men

  2019cites this paper
• Potential for early antiretroviral therapy to reduce central nervous system HIV-1 persistence.

  2019cites this paper
• The effects of antiretroviral therapy initiation time on HIV reservoir size in Chinese chronically HIV infected patients: a prospective, multi-site cohort study

  2019cites this paper
• HIV-1 Elimination in Humanized Mice

  2019cites this paper
• Mechanisms of HIV-1 Persistence and Post-Treatment Control

  2019cites this paper
• Établissement et persistance du réservoir du VIH chez des individus traités très tôt en phase aigüe de l’infection (cohorte RV254)

  2019cites this paper
• Immune Activations and Viral Tissue Compartmentalization During Progressive HIV-1 Infection of Humanized Mice

  2019cites this paper
• Lessons learned from HIV antiretroviral treatment interruption trials

  2018cites this paper
• HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers

  2018cites this paper
• HIV control: Is getting there the same as staying there?

  2018cites this paper
• Long-term Therapeutic Impact of the Timing of Antiretroviral Therapy in Patients Diagnosed With Primary Human Immunodeficiency Virus Type 1 Infection

  2018cites this paper
• Immune suppressive cells in chronic HIV-1 infection

  2018cites this paper
• The B-Cell Follicle in HIV Infection: Barrier to a Cure

  2018cites this paper
• CRISPR/Cas9 and Genome Editing for Viral Disease-Is Resistance Futile?

  2018cites this paper
• After 18 months of antiretroviral therapy, total HIV DNA decreases more pronouncedly in patients infected by CRF01_AE than in those infected by subtype B and CRF07_BC

  2018cites this paper
• New Antiretrovirals for HIV and Antivirals for HBV

  2017cites this paper
• Control of the HIV-1 DNA Reservoir Is Associated In Vivo and In Vitro with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells

  2017cites this paper
• An analysis of functional curability on HIV infection models with Michaelis-Menten-type immune response and its generalization

  2017cites this paper
• Seguimiento y actitud terapéutica de la infección por el virus de la inmunodeficiencia humana

  2017cites this paper
• Trente années d’évolution dans la prise en charge des personnes vivant avec le virus de l’immunodéficience humaine désirant devenir parents: un changement de paradigme

  2017cites this paper
• Increasing the Clinical Potential and Applications of Anti-HIV Antibodies

  2017cites this paper
• Paucity of Intact Non-Induced Provirus with Early, Long-Term Antiretroviral Therapy of Perinatal HIV Infection

  2017cites this paper
• HIV as a Cause of Immune Activation and Immunosenescence

  2017cites this paper
• Patterns of residual HIV-1 RNA shedding in the seminal plasma of patients on effective antiretroviral therapy

  2017cites this paper
• “We Need to Deploy Them Very Thoughtfully and Carefully”: Perceptions of Analytical Treatment Interruptions in HIV Cure Research in the United States—A Qualitative Inquiry

  2017cites this paper
• Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy

  2017cites this paper
• Post-treatment HIV controllers or spontaneous controllers in disguise?

  2017cites this paper
• Wake me up before you go: a strategy to reduce the latent HIV reservoir.

  2017cites this paper
• Efficacy Trials and Progress of HIV Vaccines

  2017cites this paper
• Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection

  2017cites this paper
• Cell and gene therapy strategies to eradicate HIV reservoirs

  2016cites this paper
• People living with HIV and procreation: 30 years of progress from prohibition to freedom?

  2016cites this paper
• Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial

  2016cites this paper
• Persistent But Not Replicating HIV-1 Cell-Associated DNA in Semen of Long-Term ART Experienced Men.

  2016cites this paper
• Diagnosing acute HIV infection at point of care: a retrospective analysis of the sensitivity and specificity of a fourth-generation point-of-care test for detection of HIV core protein p24

  2016cites this paper
• Polyfunctional HIV-specific T cells in Post-Treatment Controllers.

  2016cites this paper
• Animal Models for HIV Cure Research

  2016cites this paper
• Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control

  2016cites this paper
• Seminal HIV-1 RNA Detection in Heterosexual African Men Initiating Antiretroviral Therapy.

  2016cites this paper
• Compartmentalized HIV rebound in the central nervous system after interruption of antiretroviral therapy

  2016cites this paper
• Early age at start of antiretroviral therapy associated with better virologic control after initial suppression in HIV-infected infants

  2016cites this paper
• Le traitement de la primo-infection par VIH : un pas vers la rémission

  2016cites this paper
• Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection

  2016cites this paper
• Barriers to HIV Cure

  2016cites this paper
• Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability

  2016cites this paper
• Kill: boosting HIV-specific immune responses

  2016cites this paper
• Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation

  2015cites this paper
• Exploring the Potential of Monoclonal Antibody Therapeutics for HIV-1 Eradication

  2015cites this paper
• HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide?

  2015cites this paper
• Very early combination antiretroviral therapy in infants: prospects for cure

  2015cites this paper
• Broadening of Virus-Specific CD8+ T-Cell Responses Is Indicative of Residual Viral Replication in Aviremic SIV Controllers

  2015cites this paper
• The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency

  2015cites this paper
• Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes

  2015cites this paper
• HIV-serodiscordant couples desiring a child: 'treatment as prevention,' preexposure prophylaxis, or medically assisted procreation?

  2015cites this paper
• Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy

  2015cites this paper
• Evaluation of the effect of short-term treatment with the integrase inhibitor raltegravir (Isentress) on the course of progressive feline leukemia virus infection.

  2015cites this paper
• Rate and Determinants of Residual Viremia in Multidrug-Experienced Patients Successfully Treated with Raltegravir-Based Regimens

  2015cites this paper
• Complex and multi-allelic copy number variation in human disease

  2015cites this paper
• Post-treatment control: A functional cure for HIV

  2015cites this paper
• Posttreatment controllers: what do they tell us?

  2015cites this paper
• Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).

  2015cites this paper
• Toward a cure for HIV—Seeking effective therapeutic vaccine strategies

  2015cites this paper
• Initiation of Antiretroviral Therapy (ART) at Different Stages of HIV-1 Disease Is Not Associated with the Proportion of Exhausted CD8+ T Cells

  2015cites this paper
• A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control

  2015cites this paper
• A novel non-integrative single-cycle chimeric HIV lentivector DNA vaccine.

  2015cites this paper
• No evidence of posttreatment control after early initiation of antiretroviral therapy

  2015cites this paper
• Immunité et protection induites par un lentivecteur ADN innovant chez les modèles animaux de vaccination VIH-1.

  2015cites this paper
• Prise en charge de la primo-infection VIH-1

  2015cites this paper
• Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission.

  2015cites this paper
• Impaired sperm motility in HIV-infected men: an unexpected adverse effect of efavirenz?

  2015cites this paper
• HIV-1 Latency: An Update of Molecular Mechanisms and Therapeutic Strategies

  2014cites this paper
• Post-treatment Controllers

  2014cites this paper
• How a single patient influenced HIV research--15-year follow-up.

  2014cites this paper
• Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy

  2014cites this paper